143 related articles for article (PubMed ID: 38734788)
1. DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
Karami A; Skorski T
Leukemia; 2024 Jun; 38(6):1407-1410. PubMed ID: 38734788
[No Abstract] [Full Text] [Related]
2. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia.
Park S; Kim YJ; Huh HJ; Chung HS; Lee M; Park YM; Mun YC; Seong CM; Huh J
Hematology; 2021 Dec; 26(1):904-913. PubMed ID: 34789078
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells.
Zhang W; Wu H; Yang M; Ye S; Li L; Zhang H; Hu J; Wang X; Xu J; Liang A
Oncotarget; 2016 Mar; 7(12):13538-50. PubMed ID: 26646449
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
5. The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.
Jacoby MA; De Jesus Pizarro RE; Shao J; Koboldt DC; Fulton RS; Zhou G; Wilson RK; Walter MJ
Leukemia; 2014 Jun; 28(6):1242-51. PubMed ID: 24304937
[TBL] [Abstract][Full Text] [Related]
6. The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells.
Li D; Yu Z; Wang T; Li Y; Chen X; Wu L
Exp Cell Res; 2020 Jun; 391(2):111985. PubMed ID: 32259522
[TBL] [Abstract][Full Text] [Related]
7. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
[TBL] [Abstract][Full Text] [Related]
8. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia.
Wang SY; Chen WL; Wang ZC; Li XF; Lin SL; Gao C; Huang YM; Luo DF; Li JG; Zi YM; Yi Z; Lin Y; Lai L; Pan LL
Leuk Lymphoma; 2016 Nov; 57(11):2727-30. PubMed ID: 27064024
[No Abstract] [Full Text] [Related]
9. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
[TBL] [Abstract][Full Text] [Related]
11. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Cagnetta A; Soncini D; Orecchioni S; Talarico G; Minetto P; Guolo F; Retali V; Colombo N; Carminati E; Clavio M; Miglino M; Bergamaschi M; Nahimana A; Duchosal M; Todoerti K; Neri A; Passalacqua M; Bruzzone S; Nencioni A; Bertolini F; Gobbi M; Lemoli RM; Cea M
Haematologica; 2018 Jan; 103(1):80-90. PubMed ID: 29025907
[TBL] [Abstract][Full Text] [Related]
12. [Therapy-related acute myeloid leukemia: role of DNA repair].
Guièze R; Ravinet A; Hermet E; Maliki Y; de Botton S; Bay JO
Bull Cancer; 2011 Mar; 98(3):247-55. PubMed ID: 21427028
[TBL] [Abstract][Full Text] [Related]
13. Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia.
Gotoh N; Saitoh T; Takahashi N; Kasamatsu T; Minato Y; Lobna A; Oda T; Hoshino T; Sakura T; Shimizu H; Takizawa M; Handa H; Yokohama A; Tsukamoto N; Murakami H
Int J Hematol; 2018 Sep; 108(3):246-253. PubMed ID: 29737460
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling and predicting treatment response in acute myeloid leukemia.
Isidori A; Loscocco F; Curti A; Amadori S; Visani G
Pharmacogenomics; 2019 May; 20(7):467-470. PubMed ID: 31124415
[No Abstract] [Full Text] [Related]
15. Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia.
Schlenk RF
Haematologica; 2024 Jun; 109(6):1629-1630. PubMed ID: 38832418
[No Abstract] [Full Text] [Related]
16. Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.
Kamath GR; Tremblay D; Coltoff A; Caro J; Lancman G; Bhalla S; Najfeld V; Mascarenhas J; Taioli E
Leuk Res; 2019 Feb; 77():1-4. PubMed ID: 30594101
[No Abstract] [Full Text] [Related]
17. Association of GSTP1 inactivating polymorphism with acute myeloid leukemia and its specific chromosomal abnormalities.
Daraki A; Zachaki S; Rosmaraki F; Kalomoiraki M; Aleporou-Marinou V; Sambani C; Kollia P; Manola KN
Leuk Lymphoma; 2017 Oct; 58(10):2505-2507. PubMed ID: 28278696
[No Abstract] [Full Text] [Related]
18. DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.
Esposito MT; So CW
Chromosoma; 2014 Dec; 123(6):545-61. PubMed ID: 25112726
[TBL] [Abstract][Full Text] [Related]
19. Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.
Zhou JD; Yao DM; Han L; Xiao GF; Guo H; Zhang TJ; Li XX; Yuan Q; Yang L; Lin J; Qian J
Tumour Biol; 2017 Apr; 39(4):1010428317699123. PubMed ID: 28443469
[TBL] [Abstract][Full Text] [Related]
20. Impact of 9q deletions on the classification of patients with acute myeloid leukemia.
Balk B; Haferlach T; Meggendorfer M; Kern W; Haferlach C; Stengel A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2871-2874. PubMed ID: 30927073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
